"Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial" was originally created and published by ...

Neurons generated from stem cells (from skin fibroblasts) of a patient with sporadic Alzheimer’s disease. Visualized with a specific green fluorescent marker. Nuclei are shown in blue. Researchers ...

Researchers from the Institute for Neurosciences (IN), a joint center of the Miguel Hernández University of Elche (UMH) and the Spanish National Research Council (CSIC), who are also part of the ...

US FDA accepts Axsome Therapeutics’ supplemental New Drug Application for AXS-05 to treat Alzheimer’s disease agitation: New York Saturday, January 3, 2026, 12:00 Hrs [IST] Ax ...

Calcium alpha-ketoglutarate, a naturally occurring metabolite, can restore key memory-related brain functions that have been disrupted in Alzheimer’s disease.

Singapore has one of the highest life expectancies in the world, yet many individuals spend almost a decade in poor health ...

A molecular mechanism that significantly contributes to the progression of Alzheimer’s disease has been discovered by a research team led by neurobiologist Prof. Dr Hilmar Bading of Heidelberg ...

Scientists have discovered that inhaling xenon gas can activate brain immune cells to break down Alzheimer's-related plaques ...

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026NEW YORK, (GLOBE NEWSWIRE) -- ...